Clearmind Medicine Inc. (CMND)
| Market Cap | 2.47M -58.6% |
| Revenue (ttm) | n/a |
| Net Income | -7.90M |
| EPS | -71.49 |
| Shares Out | 1.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 51,825 |
| Open | 1.670 |
| Previous Close | 1.670 |
| Day's Range | 1.631 - 1.690 |
| 52-Week Range | 1.610 - 524.000 |
| Beta | -1.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 10, 2026 |
About CMND
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; a... [Read more]
Financial Performance
Financial StatementsNews
Clearmind files psychedelic patent application with Hong Kong Patent Office
Clearmind Medicine (CMND) announced the filing of a patent application with the Hong Kong Patent Office for psychedelic compounds targeting the treatment of Post-Traumatic Stress Disorder and other me...
Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
Vancouver, Canada, July 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (“ Clearmind ”) (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogen - deri...
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
Vancouver, Canada, July 17, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogenderived treatments for Al...
Clearmind reports positive retention results for intranasal formulation of MEAI
Clearmind Medicine (CMND) announced “compelling” ex vivo mucoadhesion results for its intranasal formulation of MEAI. “Leveraging a nasal drug-delivery system, the new formulation demonstrated markedl...
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
Vancouver, Canada, July 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering non‑hallucinogenic neuroplastogen‑derived treatments for ...
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
Principal Investigators of the Ongoing Phase I/II a Trial Highlighted Positive Early Experience with Clearmind Medicine's Non-Hallucinogenic MEAI Compound for Alcohol Use Disorder
Clearmind Medicine submits response to HHS request for information
Clearmind Medicine (CMND) announced that it has submitted a formal response to the U.S. Department of Health and Human Services, or HHS, request for information about MEAI’s potential as an…
Clearmind Medicine Responds to the U.S. Administration's RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative
Vancouver, Canada, July 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage a biotech company developing novel, non-hallucinogenic, next-generation, neuroplastogen-de...
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI
Vancouver, Canada, July 07, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage a clinical-stage biotech company focused on the discovery and development of novel, non-ha...
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
Vancouver, Canada, June 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of...
Clearmind completes treatment for all participants in Part A of CMND-100 trial
Clearmind Medicine (CMND) announced the completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder,…
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
Vancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of...
Clearmind Medicine granted U.S. patent for Binge Behavior Regulators
Clearmind Medicine (CMND) announced that it has been granted a U.S. Patent, No. 12,350,242, titled “Binge Behavior Regulators”, by the United States Patent and Trademark Office, USPTO. The patent, whi...
Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators
Vancouver, Canada, June 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of...
Clearmind Medicine completes dosing for four cohorts of CMND-100 trial
Clearmind Medicine (CMND) announced the successful completion of dosing for all 24 participants in Cohorts 1 through 4 of Part A of its ongoing Phase I/II clinical trial evaluating CMND-100…
Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
Vancouver, Canada, June 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of...
Clearmind Medicine Quarterly report: Q2 2026
Clearmind Medicine has published its Q2 2026 quarterly earnings report on June 15, 2026.
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar
Yale and Johns Hopkins Researchers to Present Early Findings on MEAI Next Week in Live Webinar Yale and Johns Hopkins Researchers to Present Early Findings on MEAI Next Week in Live Webinar
Clearmind Medicine files Japanese patent application for 5-Methoxy-2-aminoindan
Clearmind Medicine (CMND) announced the publication of a Japanese patent application for its proprietary compositions comprising 5-Methoxy-2-aminoindan for the treatment of depression.
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
Vancouver, Canada, May 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of ...
Clearmind Medicine announces JHM-IRB approval to advance CMND-100 trial
Clearmind Medicine (CMND) announced that the Johns Hopkins Medicine Institutional Review Board, JHM-IRB, has granted approval for its ongoing Phase I/II clinical trial of CMND-100. Dr. Adi Zuloff-Shan...
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
Vancouver, Canada, May 26, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of ...
Clearmind Medicine Inc trading halted, news pending
19:50 EDT Clearmind Medicine (CMND) Inc trading halted, news pending
Clearmind Medicine announces 1-for-10 reverse share split
Clearmind Medicine (CMND) announced that it will conduct a reverse share split of its issued and outstanding common shares, no par value, at a ratio of 1-for-10. The reverse split…
Clearmind Medicine Announces 1-for-10 Reverse Share Split
Vancouver, Canada, May 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of ...